(Q39253839)

10 September 2017

title

The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. (English)

1 reference

10 September 2017

0 references

Dario Neri

4

0 references

author name string

Kathrin Schwager

series ordinal

1

1 reference

10 September 2017

Teresa Hemmerle

series ordinal

2

1 reference

10 September 2017

David Aebischer

series ordinal

3

1 reference

10 September 2017

language of work or name

English

0 references

publication date

25 October 2012

1 reference

Journal of Investigative Dermatology

10 September 2017

published in

1 reference

10 September 2017

volume

133

1 reference

10 September 2017

issue

3

1 reference

10 September 2017

page(s)

751-758

1 reference

https://scigraph.springernature.com/pub.10.1038/jid.2012.376

10 September 2017

exact match

0 references

cites work

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Evidence of ED-B+ fibronectin synthesis in human tissues by non-radioactive RNA in situ hybridization. Investigations on carcinoma (oral squamous cell and breast carcinoma), chronic inflammation (rheumatoid synovitis) and fibromatosis (Morbus Dupuyt

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Selective targeted delivery of TNFalpha to tumor blood vessels.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Systematic review of medical treatment in melanoma: current status and future prospects.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Treatments for metastatic melanoma: synthesis of evidence from randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Tumour vascular targeting

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Immunocytokines: a novel class of potent armed antibodies

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Antibody targeted drugs as cancer therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

High response rate after intratumoral treatment with interleukin-2

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.376

7 January 2021

Identifiers

DOI

10.1038/JID.2012.376

1 reference

10 September 2017

1 reference